Latest Content

Dwyane Wade Talks Tumor Removal, Bachelorette Star’s Husband Cancer Diagnosis and More

January 31st 2025, 4:00pm

By Spencer Feldman

Article

From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.

Keytruda and Lenvima Combo Misses OS Mark in HER2– Gastroesophageal Cancer

January 31st 2025, 2:00pm

By Ryan Scott

Article

In the LEAP-015 trial, Keytruda and Lenvima plus chemo did not meet the primary end point of overall survival in HER2– gastroesophageal adenocarcinoma.

Galinpepimut-S Immunotherapy Has Preliminary Efficacy in Acute Myeloid Leukemia

January 30th 2025, 10:00pm

By Spencer Feldman

Article

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

Herceptin Combo Shows Limited Benefit in Gastric/GEJ Cancer

January 30th 2025, 7:43pm

By Russ Conroy

Article

In the INNOVATION trial, adding Herceptin and Perjeta to chemotherapy increased toxicity in patients with HER2-positive gastric cancers.

Strutting Into Year 11 With Metastatic Breast Cancer

January 30th 2025, 6:00pm

By Martha Carlson

Article

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with confidence and self-advocacy.

How Do Molecular Factors Impact Response to Immunotherapy in Kidney Cancer?

January 30th 2025, 4:00pm

By Ryan Scott

Video

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Itovebi-Based Treatment Has OS Benefit in PIK3CA+ HR+/HER2– Breast Cancer

January 30th 2025, 2:00pm

By Ryan Scott

Article

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

A Phase 1 Trial of Iadademstat Plus Vidaza Has Dosed a Patient With MDS

January 29th 2025, 10:00pm

By Ryan Scott

Article

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

Role of Caregivers in Managing Polycythemia Vera

January 29th 2025, 9:37pm

By Julie Huynh-Lu, P.A.

Video

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician intervention.

Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset

January 29th 2025, 8:00pm

By Russ Conroy

Article

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

Ovarian Cancer Teaches Hard Life Lessons

January 29th 2025, 6:00pm

By Kelly Irvin

Article

Having a life-threatening disease reminds me daily to make the most of whatever time I have.

A Cancer Institution is Seeking to Address Food Insecurity in Patients With Cancer

January 29th 2025, 4:00pm

By Dr. Anna Arthur

Video

Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood cancers undergoing treatment.

FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma

January 29th 2025, 2:00pm

By Ryan Scott

Article

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC

January 28th 2025, 10:00pm

By Ryan Scott

Article

The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

Brukinsa May Improve Efficacy Versus Imbruvica in R/R CLL and SLL

January 28th 2025, 7:59pm

By Spencer Feldman

Article

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.